The use of mitoxantrone plus cyclophosphamide as first‐line treatment of metastatic breast cancer

Thirty‐two patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were entered into a trial of mitoxantrone 12 mg/m² plus Cyclophosphamide 600 mg/m² given at three weekly intervals. Thirty‐one patients are eligible for assessment. Response was seen in 65% (4/31 complete regression; 16/31 partial regression). Median duration of response was 6 months and median duration of survival was 10 months. Mitoxantrone + Cyclophosphamide appears to be an active combination in treatment of metastatic breast cancer.